Regeneron Pharmaceuticals

Latest Headlines

Latest Headlines

Regeneron team IDs a candidate for ultra-rare bone disease

Back at the beginning of 2014, a fast-growing Regeneron revealed that it had been building a new genetics research center that would zero in on carefully targeted diseases as it built new drug development programs from the ground up. Eighteen months later the big biotech says the effort--led by some top researchers wooed in to run the operation--has paid off with a clear target for a rare genetic bone disease. And they have an antibody in preclinical testing that could correct the disorder.

Biopharma's 10 highest-paid heads of R&D

The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.

Japan approves Bayer sales of Eylea for diabetes-related visual impairment

Japan's Pharmaceuticals and Medical Devices Agency approved Bayer's Eylea for the treatment of diabetes-related visual impairment, the company said in a release June 26.

Science pays: 2013's 10 best-compensated R&D chiefs in biopharma

For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>

ThromboGenics is picking between billion-dollar bids, report says

Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.

Sanofi, Regeneron take the lead in blockbuster PhIII race of PCSK9 drugs

Sanofi and Regeneron have rolled out promising Phase III data on their cholesterol drug alirocumab, which handily breezed by Merck's Zetia in lowering bad LDL cholesterol. The partners are in a high-stakes race to win the first regulatory approval for a PCSK9 inhibitor.

Top 15 highest paid biopharma R&D chiefs

Being an R&D chief at a major biopharma company in today's environment of major research cutbacks, patent expirations and pressure from investors to speed new drugs to market is no easy...

In close race with Amgen, Regeneron expands late-stage PCSK9 program

After partners Regeneron and Sanofi announced more than 10 late-stage studies last year, Regeneron revealed plans Tuesday to take a shot at a trial to test less frequent dosing of the experimental therapy.

After Eylea win, Regeneron execs puzzle over R&D scale-up challenge

With a new blockbuster drug and more potential hits in development, Regeneron Pharmaceuticals has been successful long enough for top executives to consider the challenges of keeping the entrepreneurial culture behind the R&D streak alive. Read more >>

How Regeneron's Yancopoulos became the top-paid executive in biotech

Dr. George Yancopoulos is the highest paid biopharma executive in the world. In interviews with company leaders at Regeneron, FierceBiotech has learned more about why the company rewarded its chief scientist with a pay package of $81.6 million. Read more >>